Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
about
Antigen-specific immunotherapy of cervical and ovarian cancerChimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumorsVirus-like particles: a new family of delivery systems.Therapeutic HPV DNA vaccines.Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccinePapillomavirus-like particle based vaccines: cervical cancer and beyond.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Preventative and therapeutic vaccines for cervical cancer.A randomized trial of immunotherapy for persistent genital wartsVirus-like particles: flexible platforms for vaccine development.Physical interaction of human papillomavirus virus-like particles with immune cells.Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice.Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
P2860
Q27488697-9E008CD2-4AD2-43AB-8238-E1B8211568D3Q28484683-4AD2280A-B4C6-4EFA-AEA8-6700CEBD164BQ30817169-0E508AAA-028B-4216-A9F1-A6648B1012A0Q33936427-E80E431F-8EF5-479F-9179-4E468E758B14Q34343006-E9A4BBC1-696E-498F-A7B4-30EBE0F052D9Q34451862-A4F81502-D9AA-4BDD-B121-0E8958D26EC1Q35194178-F3498DA8-EB21-4A8D-BCF8-B7CE8CB588C5Q35552591-5400DD51-A6E2-4DB8-B199-5109AA46DC90Q35623323-760D83EB-9DB8-4754-8269-D4F4D5185132Q36391858-527375EF-7AD7-41A4-85F5-0EE70476F6E4Q36837144-A6A8F772-0215-4DED-A8CE-5867B363AB92Q38301730-47003585-F3DF-45DF-8B9B-1E011FF8B124Q38618258-AC9208A3-F1B3-425D-9709-2FB0085DB7E7Q38635840-131D7641-0DC3-4ED3-9073-8DE964957106Q40012120-CE94EB80-E24A-4CB0-84D8-5FB5CDC41C9DQ40082278-C1439590-678B-4335-B377-7FACEF50C37AQ40957603-B217B2AE-20E1-4689-8CB7-57BE43E02B53Q41830085-2D6557BD-7496-4D3C-BB86-11B841CC7E5CQ42273331-4583D25E-C632-491F-A933-2A4F983F6B2BQ56959423-3B6C37A3-B0FB-46C4-887A-1A9DDEBF32B3
P2860
Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Papillomavirus virus-like part ...... es to the MHC class I pathway.
@en
type
label
Papillomavirus virus-like part ...... es to the MHC class I pathway.
@en
prefLabel
Papillomavirus virus-like part ...... es to the MHC class I pathway.
@en
P2093
P356
P1433
P1476
Papillomavirus virus-like part ...... pes to the MHC class I pathway
@en
P2093
P304
P356
10.1006/VIRO.1997.8912
P407
P50
P577
1998-01-01T00:00:00Z